Floatz logo

Elimusertib

Fallopian Tube High Grade Serous Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Fallopian Tube High Grade Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
NRG Oncology
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Ohio State University Comprehensive Cancer Center
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB

View all 39 →

Same molecule, other indications

Elimusertib is also rated in:

Recurrent Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Ewing sarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
alveolar rhabdomyosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →